Arius Announces New Findings In Cancer Antibody Programs

Cancer Antibody Programs

ARIUS Research presented new findings from its Trop-2 and CD59 antibody programs.

ARIUS scientists will discuss the Company's Trop-2 and CD59 abstracts at the AACR press conference today at 9:30 a.m. PT.

"Both our Trop-2 and CD59 antibody programs have demonstrated novel approaches in treating cancer. Our Trop-2 antibody is a novel target and has been linked to aggressive cancers in the scientific literature, while our CD59 program has demonstrated the ability to foil a cancer cell's ability to evade the immune system," said Dr. David Young, President and CEO. "These programs, in addition to our CD44 cancer stem cell program, were generated through our proprietary drug discovery technology, FunctionFIRST(TM), which is inherently designed to produce novel antibodies and identify unique cancer targets."

Trop-2 Proffered Paper Presentation

ARIUS' Trop-2 targeting antibody has demonstrated a significant anti-tumor effect in animal models of human pancreatic cancer, inhibiting tumor growth by up to 100 percent. Subsequent testing showed efficacy in animal models of breast, colon and prostate cancers. The antibody compared favorably with Taxotere in prostate cancer model and has also shown the ability to be highly potent at low-dose concentrations.

Additional information can be found at the AACR-NCI-EORTC 2007 International Conference on Molecular Targets and Cancer Therapeutics in San Francisco at the following location and time: AR47A6.4.2, a functional naked monoclonal antibody targeting Trop-2, demonstrates in vivo efficacy in human pancreatic, colon, breast and prostate cancer models. Proffered Paper Session 3, Thursday, October 25, 2007 from 5:15 - 5:30 p.m. in the Third Floor Ballroom at Moscone Center.

CD59 Poster Presentation

ARIUS has demonstrated that CD59 is commonly used to protect cancer cells from being destroyed. Our CD59 targeting antibody provides a novel approach to "de-cloak" cancers. The CD59 targeting antibody activates complement activity against cancer cells and inhibits tumor growth in animal models of breast, colon, lung and prostate. In animal models of breast cancer, tumor growth was inhibited by up to 100 percent. In particular, the potent effect was observed in breast cancer models that represent a patient population that cannot be treated by Herceptin, the only therapeutic antibody currently approved for breast cancer treatment.

ARIUS' CD59 poster was presented at the AACR-NCI-EORTC 2007 International Conference on Molecular Targets and Cancer Therapeutics in San Francisco on Tuesday October 23, 2007 and is entitled "AR36A36.11.1, a monoclonal antibody targeting CD59, enhances complement activity and exhibits potent in vivo efficacy in multiple human cancer models."